Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users.
The humoral response (haemagglutination inhibiting antibodies) to trivalent split influenza vaccine for the 1993-94 winter season (A/Beijing/32/92 (H3N2), A/Singapore/6/86 (H1N1) and B/Panama/45/90) was evaluated in a group of young HIV-seropositive ex-intravenous heroin users and compared with responses measured in HIV-seronegative individuals with a similar history. HIV-negative volunteers showed an overall positive response suggesting that previous heroin use did not influence their humoral response to influenza vaccine. Comparable results were obtained in HIV-positive subjects with CD4+ lymphocyte counts > 500 microliters-1, whereas impaired reactivity was found in HIV-positive volunteers with CD4+ counts < 500 microliters-1. Booster vaccination did not increase antibody levels in any of the groups studied, although the data did not exclude a positive influence of a second vaccine dose on persistence of antibody at 120 days after the first dose. No significant changes were observed in p24 antigenemia levels in HIV-positive individuals after vaccination.
Iorio
A M
AM
Department of Hygiene, University of Perugia, Italy.
Alatri
A
A
Francisci
D
D
Preziosi
R
R
Neri
M
M
Donatelli
I
I
Castrucci
M R
MR
Biasio
L R
LR
Tascini
C
C
Iapoce
R
R
Pierucci
P
P
Baldelli
F
F
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D018791:CD4 Lymphocyte Count; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D018023:HIV Seronegativity / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015819:Substance Abuse, Intravenous / Q000150:complications*
D000914:Antibodies, Viral; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D007252:Influenza Vaccines